Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2555854rdf:typepubmed:Citationlld:pubmed
pubmed-article:2555854lifeskim:mentionsumls-concept:C0206679lld:lifeskim
pubmed-article:2555854lifeskim:mentionsumls-concept:C0003392lld:lifeskim
pubmed-article:2555854lifeskim:mentionsumls-concept:C0015133lld:lifeskim
pubmed-article:2555854lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2555854lifeskim:mentionsumls-concept:C0598312lld:lifeskim
pubmed-article:2555854lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:2555854pubmed:issue5lld:pubmed
pubmed-article:2555854pubmed:dateCreated1990-1-4lld:pubmed
pubmed-article:2555854pubmed:abstractTextThe anti-human herpesvirus type 1 (herpes simplex virus 1; HSV1) activity of etoposide (VP-16-213, a semi-synthetic derivative of epipodophyllotoxin) was investigated in vitro. Etoposide (but not the proprietary solvent in which the compound is usually formulated) demonstrated a significant antiviral action, probably through an effect on virus replication. Etoposide, at 3 micrograms/ml, induced a 50% reduction of HSV1-plaque formation in Vero cells. These findings are considered in the context of the use of etoposide in an in vivo procedure for the diagnosis of herpes encephalitis through virus-specific scintigraphic brain imaging.lld:pubmed
pubmed-article:2555854pubmed:languageenglld:pubmed
pubmed-article:2555854pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2555854pubmed:citationSubsetIMlld:pubmed
pubmed-article:2555854pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2555854pubmed:statusMEDLINElld:pubmed
pubmed-article:2555854pubmed:issn0923-2516lld:pubmed
pubmed-article:2555854pubmed:authorpubmed-author:LongsonMMlld:pubmed
pubmed-article:2555854pubmed:authorpubmed-author:LewisA GAGlld:pubmed
pubmed-article:2555854pubmed:authorpubmed-author:KlapperP EPElld:pubmed
pubmed-article:2555854pubmed:authorpubmed-author:CleatorG MGMlld:pubmed
pubmed-article:2555854pubmed:authorpubmed-author:TempletonP...lld:pubmed
pubmed-article:2555854pubmed:issnTypePrintlld:pubmed
pubmed-article:2555854pubmed:volume140lld:pubmed
pubmed-article:2555854pubmed:ownerNLMlld:pubmed
pubmed-article:2555854pubmed:authorsCompleteYlld:pubmed
pubmed-article:2555854pubmed:pagination443-51lld:pubmed
pubmed-article:2555854pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:2555854pubmed:meshHeadingpubmed-meshheading:2555854-...lld:pubmed
pubmed-article:2555854pubmed:meshHeadingpubmed-meshheading:2555854-...lld:pubmed
pubmed-article:2555854pubmed:meshHeadingpubmed-meshheading:2555854-...lld:pubmed
pubmed-article:2555854pubmed:meshHeadingpubmed-meshheading:2555854-...lld:pubmed
pubmed-article:2555854pubmed:meshHeadingpubmed-meshheading:2555854-...lld:pubmed
pubmed-article:2555854pubmed:meshHeadingpubmed-meshheading:2555854-...lld:pubmed
pubmed-article:2555854pubmed:meshHeadingpubmed-meshheading:2555854-...lld:pubmed
pubmed-article:2555854pubmed:meshHeadingpubmed-meshheading:2555854-...lld:pubmed
pubmed-article:2555854pubmed:articleTitleEffects of the anti-cancer agent etoposide on human herpesvirus 1 replication in vitro.lld:pubmed
pubmed-article:2555854pubmed:affiliationDept of Medical Microbiology, University of Manchester, Medical School, UK.lld:pubmed
pubmed-article:2555854pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2555854pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2555854lld:pubmed